Loading…
← CockpitCompetitor Analysis › 4569.T KYORIN Pharmaceutical Co.,Ltd.Open in the cockpit ↗

KYORIN Pharmaceutical Co.,Ltd.4569.TCompetitor analysis, valuation and peers

Japan · JPY·Health Care›Pharmaceuticals: Major
Momentum weak 38
Mkt cap
$360M
US dollars, full cap
Free float
61%
of shares outstanding
$/day
$1.18M
20-day average traded
Fwd P/E
35.5×
forward earnings
ROIC−WACC
-3.7 pp
WACC 5.0%
Hurdle
+2 pp
Req g minus delivered
Next earnings
78 days
4 Feb 2027
Close · JPY¥1,108
1D-0.7%
1W+5.9%
1M+0.2%
3M-0.9%
6M-22.0%
YTD-27.9%
1Y-21.8%
ATR %2.5%
52w lowhigh35.8% off high

What KYORIN Pharmaceutical does

Employees: 1,982

KYORIN Pharmaceutical at a glance

Size KYORIN Pharmaceutical (4569.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $360M, the 1242nd largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥1,108 on 18 Nov 2026.

Performance Over six months the shares fell 22.0%, against -23.8% for the median peer and -1.4% for the Japan market (cap-weighted) — 8th highest of 19 in its peer set.

Growth Revenue fell 6.5% over the last twelve months (peer median -1.1%); the operating margin is 2.0% (peer median -13.0%).

Valuation It trades at 35.5× forward earnings against a peer median of 16.0× (2nd most expensive of 5).

Price implies For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is +2 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 3.7 points below its cost of capital (5.0% WACC).

Next results Next results expected around 4 Feb 2027 (exchange calendar; dates can move).

Relative performance

809010021 May 202621 Aug 202618 Nov 20264569.T 78Peer median 77
Six months, rebased to 100: KYORIN Pharmaceutical against the median of its 20 peers (local-currency closes).

KYORIN Pharmaceutical financials

Reported figures in JPY; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue¥125B¥126B¥130B¥120B¥113B
Revenue growth—-3%+9%+6%—
Gross profit¥49.1B¥51.6B¥59.5B¥51.6B¥50.2B
EBITDA¥7.19B¥8.22B¥17.1B¥10.5B¥8.96B
Net income¥388M¥3.45B¥9.09B¥5.47B¥4.72B
Free cash flown/a¥2.52B-¥2.19B-¥4.23B-¥4.32B
Capital expendituren/a¥3.98B¥6.29B¥6.25B¥9.40B
Total debt¥23.2B¥23.8B¥28.4B¥20.9B¥21.3B

Quarterly statements and history in the cockpit →

KYORIN Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-75%-50%-25%0%+25%-20%0%UNICHEMLAB3010890001530056904886301111MPLT002872SPRYPBYI688399IRD455200286830053442C4569.T6-month return →1-month return →
Up and to the right = strong over both horizons. KYORIN Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%0×200×400×0056904886PBYI45524569.TRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. KYORIN Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

0%+20%0%20%000153005690600594002872PBYI3005344569.TGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. KYORIN Pharmaceutical is the large dot.

KYORIN Pharmaceutical competitors and peer comparison

How KYORIN Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

KYORIN Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure4569.TPeer medianRank in peer set
1-month return+0.2%-13.3%3rd highest of 20
6-month return-22.0%-23.8%8th highest of 19
Distance from 52-week high-35.8%-41.3%9th highest of 21
Revenue growth (TTM)-6.5%-1.1%9th lowest of 18
Operating margin2.0%-13.0%7th highest of 18
Forward P/E35.5×16.0×2nd most expensive of 5
Growth the price implies (Req g, 7 yrs)6.7%5.8%4th least demanding of 7
Growth delivered (Del g)+4.2%+1.7%3rd highest of 7
Hurdle (Req g minus delivered)+2.5 pp+0.2 pp3rd most demanding of 7
ROIC minus cost of capital-3.7 pp-7.2 pp7th highest of 16
EV / EBITDA8.0×15.7×2nd cheapest of 6
Net debt / EBITDA-0.0×0.2×3rd least indebted of 6

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
KYORIN Pharmaceutical 4569.TJapan$360M-22%-6%2%35.5×6.7%+4.2%
Unichem Laboratories UNICHEMLAB.NSIndia$361M+28%+6%5%n/an/an/a
Tuoxin Pharmaceutical 301089.SZChina$363M-28%+17%-20%n/an/an/a
Anhui Fengyuan Pharmaceutical 000153.SZChina$355M-17%-24%3%n/a3.6%+3.1%
Pharmicell 005690.KSSouth Korea$364M-55%+46%32%8.2×-7.9%+24.8%
ASKA Pharmaceutical 4886.TJapan$354M-24%+11%n/a12.9×n/an/a
Guangdong Lifestrong Pharmacy 301111.SZChina$368M-33%+7%-2%n/an/an/a
6467 6467.TWTaiwan$368Mn/an/a-2,618%n/an/an/a
Guizhou Yibai Pharmaceutical 600594.SSChina$351M-23%-26%-15%n/a8.0%-11.3%
MapLight Therapeutics MPLTUnited States$370M-76%n/an/an/an/an/a
Tiansheng Pharmaceutical 002872.SZChina$371M-1%-1%-13%n/a22.2%-15.7%
ARS Pharmaceuticals SPRYUnited States$371M-53%-14%-162%n/an/an/a
Puma Biotechnology PBYIUnited States$373M+3%+9%11%19.0×0.1%+0.3%
Jiangsu Bioperfectus Technologies 688399.SSChina$374M-51%-8%-23%n/an/an/a
Opus Genetics IRDUnited States$379M-22%-46%-778%n/an/an/a
JCR Pharmaceuticals 4552.TJapan$379M-5%+3%-14%398.3×n/an/a
Lifecome Biochemistry 002868.SZChina$384M-54%-23%-3%n/an/an/a
SanBio 4592.TJapan$386M-55%n/an/an/an/an/a
Gansu Longshenrongfa Pharmaceutical Industry 300534.SZChina$386M-2%-21%8%n/a20.9%+28.2%
Shukra Pharmaceuticals SHUKRAPHAR.NSIndia$387Mn/a+222%54%n/an/an/a
iX Biopharma 42C.SISingapore$387M+28%-12%-140%n/an/an/a

Questions

Which companies are KYORIN Pharmaceutical's closest peers?
The cockpit's peer set: Unichem Laboratories (UNICHEMLAB.NS), Tuoxin Pharmaceutical (301089.SZ), Anhui Fengyuan Pharmaceutical (000153.SZ), Pharmicell (005690.KS), ASKA Pharmaceutical (4886.T), Guangdong Lifestrong Pharmacy (301111.SZ), 6467 (6467.TW), Guizhou Yibai Pharmaceutical (600594.SS).
Is KYORIN Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 35.5× against a peer median of 16.0×, 2nd most expensive of 5 in its peer set. For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is +2 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has KYORIN Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -22.0% against -23.8% for the median peer; over one year -21.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.